Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erythromycin + lobaplatin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intrapleural
01
Overview
Erythromycin + lobaplatin is a combination therapy used intrapleurally for the treatment of malignant pleural effusion in non-small cell lung cancer (NSCLC) patients. This combination has shown to be safe and efficient in clinical studies. Lobaplatin is a third-generation platinum anticancer drug, while erythromycin is a macrolide antibiotic. When administered intrapleurally, this combination has demonstrated effective control of pleural effusion with manageable adverse effects.
02
Targets
DNA23S rRNA (23S ribosomal RNA)
Beyond the preview
Go deeper on erythromycin + lobaplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erythromycin + lobaplatin.